EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 10
Issue: 6
22-24
Year: 2023

ADDRESSING UNMET NEEDS IN HEMOPHILIA QUALITY OF LIFE IN LOW- AND MIDDLE-INCOME COUNTRIES: CHALLENGES AND STRATEGIES FOR IMPROVEMENT

Adela Perolla*

University Hospital Centre "Mother Teresa", Service of Hematology, Tirana, Albania.

***Corresponding Author: Adela Perolla**
University Hospital Centre "Mother Teresa", Service of Hematology, Tirana, Albania.

Article Received on 27/03/2023 **Article Revised on 17/04/2023** **Article Accepted on 07/05/2023**

ABSTRACT
Hemophilia, a genetic bleeding disorder characterized by a deficiency in clotting factors, affects millions of people worldwide, with the quality of life (QoL) for affected individuals remaining suboptimal, particularly in low- and middle-income countries (LMICs). This article discusses the unmet needs in hemophilia care and management in LMICs, highlighting challenges and potential strategies for improvement. Key areas of focus include limited access to comprehensive care, prophylactic treatment challenges, personalized treatment barriers, pain management gaps, mental health support, caregiver support, education and awareness, employment and financial support, and integration of telehealth and digital health technologies. By employing a multifaceted approach involving governments, healthcare systems, international organizations, and patient advocacy groups, it is possible to significantly improve the QoL for individuals with hemophilia in these regions.

KEYWORDS: Hemophilia, quality of life, low- and middle-income countries, comprehensive care, prophylactic treatment, personalized treatment, pain management, mental health support, caregiver support, education and awareness, employment and financial support telehealth and digital health technologies.

INTRODUCTION
Hemophilia, a genetic bleeding disorder characterized by a deficiency in clotting factors, affects millions of people worldwide, with an estimated 400,000 individuals suffering from severe forms of the disease (World Federation of Hemophilia, 2020). Despite advancements in treatment, the quality of life (QoL) for individuals with hemophilia remains suboptimal, particularly in low- and middle-income countries (LMICs). This article aims to discuss the unmet needs in hemophilia care and management in LMICs, highlighting challenges and potential strategies for improvement.

MATERIALS AND METHODS
Literature Review: A comprehensive literature review was conducted to gather information on the challenges faced by individuals with hemophilia in low- and middle-income countries (LMICs) and potential strategies for improving their quality of life. Electronic databases such as PubMed, Scopus, and Web of Science were searched using relevant keywords, including "hemophilia," "quality of life," "low- and middle-income countries," "comprehensive care," "prophylactic treatment," "personalized treatment," "pain management," "mental health support," "caregiver support," "education and awareness," "employment and financial support," and "telehealth and digital health technologies." The search was limited to articles published in English between 2000 and 2021. The inclusion criteria for selecting articles were relevance to the topic, methodological rigor, and contribution to the existing knowledge in the field.

Synthesis of Information: The information gathered from the literature review was synthesized and organized according to the identified themes, which include limited access to comprehensive care, prophylactic treatment challenges, personalized treatment barriers, pain management gaps, mental health support, caregiver support, education and awareness, employment and financial support, and integration of telehealth and digital health technologies. Each theme was discussed in detail, highlighting the challenges faced by individuals with hemophilia in LMICs and the potential strategies for addressing these challenges.

RESULTS
The results of this study provide an overview of the unmet needs and challenges faced by individuals with hemophilia in low- and middle-income countries (LMICs) as well as potential strategies for improving

their quality of life. The findings are organized according to the identified themes:

Limited access to comprehensive care

In many LMICs, access to comprehensive care services, including diagnosis, treatment, and rehabilitation, is severely limited (Srivastava et al., 2013). Insufficient healthcare infrastructure, lack of trained healthcare professionals, and inadequate funding often contribute to these disparities. Strategies to address this issue include strengthening healthcare systems, increasing investment in hemophilia care, and fostering international partnerships to improve access to essential resources (Riva, 2019). Additionally, community-based initiatives and telemedicine approaches can help bridge the gap in access to care for rural and underserved populations (Nascimento et al., 2014).

Prophylactic treatment challenges

Prophylactic treatment with clotting factor concentrates is considered the gold standard for managing severe hemophilia. However, in LMICs, the availability of these treatments is often limited, and patients may rely on on-demand treatment or blood transfusions (Ndoumba-Mintya A, 2023). Expanding access to affordable prophylactic treatments is crucial for improving QoL in these regions. Initiatives like the World Federation of Hemophilia's Humanitarian Aid Program have provided support in this area, but more work is needed to ensure sustainable access to treatments (World Federation of Hemophilia, 2020). Local manufacturing and public-private partnerships can also help increase the availability and affordability of clotting factor concentrates (Forsyth et al., 2013).

Personalized treatment barriers

Hemophilia is a complex disorder, and personalized treatment strategies can significantly improve patient outcomes. However, access to genetic testing and individualized care remains a challenge in LMICs (Saxena, 2013). To address this need, governments and international organizations should prioritize investments in diagnostic capabilities and targeted therapies, with particular emphasis on increasing genetic testing capacity and implementing novel therapies like gene therapy and novel non-factor replacement therapies (Pipe, 2021).

Pain management gaps

Chronic pain, primarily due to joint damage, is a common issue for individuals with hemophilia. In LMICs, pain management options may be limited, impacting daily activities and overall QoL (Saxena, 2013). Developing effective and affordable pain management strategies, including pharmacological and non-pharmacological interventions, should be a priority for these regions. Multidisciplinary approaches to pain management, involving physical therapy, occupational therapy, and psychological interventions, can be particularly beneficial (Stromer W et al., 2021).

Mental health support

The psychological burden of living with hemophilia, including anxiety, depression, and social isolation, is often overlooked in LMICs. Providing access to mental health services, support groups, and educational resources can help improve emotional well-being and QoL for affected individuals (Blanchette et al., 2017). Cultural and community-based approaches to mental health support can also help address the unique needs and challenges faced by people with hemophilia in LMICs (Shrivastava et al., 2013).

Support for caregivers

Caregivers play a critical role in the lives of people with hemophilia but often face significant emotional, financial, and physical burdens (Curtis et al., 2020). Providing support and resources for caregivers is essential for improving QoL for both the individual with hemophilia and their caregiver. Strategies to support caregivers in LMICs include offering educational programs, respite care services, financial assistance, and access to support groups and counseling services.

Education and Awareness

Greater public understanding of hemophilia is needed to reduce stigma, improve access to care, and facilitate better social integration for people with hemophilia in LMICs. Educational campaigns targeting healthcare providers, schools, and the general public can help raise awareness and promote accurate understanding of the disorder (Saxena, 2013). Collaboration with local patient organizations and community leaders can also help ensure that educational efforts are culturally relevant and effective.

Employment and Financial support

Living with hemophilia can be costly, and many individuals face challenges in maintaining employment due to their health. Ensuring access to appropriate employment and financial support is crucial for improving QoL in LMICs. Governments and non-governmental organizations can work together to develop policies and programs that support individuals with hemophilia in finding suitable employment, provide workplace accommodations, and offer financial assistance for medical expenses.

Integration of Telehealth and Digital health technologies

The use of telehealth and digital health technologies can help improve access to care, patient monitoring, and self-management for people with hemophilia in LMICs (Iorio et al., 2018). Implementing telemedicine services, mobile health applications, and electronic health record systems can help streamline care delivery and empower patients to better manage their condition. Additionally, these technologies can support ongoing education and communication between patients, caregivers, and healthcare providers.

CONCLUSION

Addressing the unmet needs in hemophilia QoL in LMICs is a complex challenge, requiring a multifaceted approach involving governments, healthcare systems, international organizations, and patient advocacy groups. By focusing on improving access to comprehensive care, expanding prophylactic treatment options, promoting personalized care, enhancing pain management, fostering mental health support, supporting caregivers, raising education and awareness, providing employment and financial support, and integrating telehealth and digital health technologies, it is possible to significantly improve the QoL for individuals with hemophilia in these regions.

ACKNOWLEDGMENTS

I would like to express my deepest gratitude to the numerous healthcare professionals, policymakers, and patient advocacy organizations working tirelessly to improve the quality of life for individuals with hemophilia in low- and middle-income countries. Their dedication and expertise have been invaluable in shaping the insights presented in this article.

Lastly, I would like to acknowledge the individuals living with hemophilia and their caregivers, who continue to demonstrate resilience and courage in the face of adversity. Their experiences and perspectives have been essential in shaping the understanding of the challenges and potential solutions presented in this article.

REFERENCES

1. Ndoumba-Mintya A, Diallo YL, Tayou TC, Mbanya DN. Optimizing Haemophilia Care in Resource-Limited Countries: Current Challenges and Future Prospects. J Blood Med, 2023; 20, 14: 141-146. doi: 10.2147/JBM.S291536. PMID: 36846349; PMCID: PMC9951595.
2. Blanchette, N., Rivard, G., Israels, S., & Robinson, S. Canadian Hemophilia Outcomes–Kids' Life Assessment Tool (CHO-KLAT) Version 2.0: Measuring health-related quality of life of boys with hemophilia in low- and middle-income countries. Pediatric Blood & Cancer, 2017; 64(5): e26285.
3. Curtis, R., Baker, J., Riske, B., Ullman, M., & the Partners in Bleeding Disorders Evaluation (PIBE) Working Group. The impact of hemophilia on caregivers: Results from the Hemophilia Utilization Group Study – Part V (HUGS V). Patient, 2020; 13(4): 457-467.
4. Forsyth AL, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. Haemophilia, 2014; 20(1): 44-51. doi: 10.1111/hae.12239. Epub 2013 Aug 1. PMID: 23902228.
5. Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, Tunis S; coreHEM panel. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. Haemophilia, 2018; 24(4): e167-e172. doi: 10.1111/hae.13504. Epub 2018 May 20. PMID: 29781145.
6. Stromer W, Pabinger I, Ay C, Crevenna R, Donnerer J, Feistritzer C, Hemberger S, Likar R, Sevelda F, Thom K, Wagner B, Streif W. Pain management in hemophilia: expert recommendations. Wien Klin Wochenschr, 2021; 133(19-20): 1042-1056. doi: 10.1007/s00508-020-01798-4. Epub 2021 Mar 4. PMID: 33661391; PMCID: PMC8500904.
7. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth, 2014; 113(6): 922-34. doi: 10.1093/bja/aeu158. Epub 2014 Jun 27. PMID: 24972790; PMCID: PMC4627369.
8. Pipe, SW. Delivering on the promise of gene therapy for haemophilia. *Haemophilia*, 2021; 27(3): 114–121. https://doi.org/10.1111/hae.14027
9. Riva, S. Hemophilia care in low- and middle-income countries: Overcoming the challenges. Seminars in Thrombosis and Hemostasis, 2019; 45(7): 675-681.
10. Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med, 2013; 16, 4: 49-56. doi: 10.2147/JBM.S43734. PMID: 23700376; PMCID: PMC3660133.
11. Shrivastava, A., Myles, P. R., Makris, M., Alikhan, R., & Ludlam, C. A. Quality of life assessment in the multinational ITI study. Haemophilia, 2017; 23(4): e327-e329.
12. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia, 2013; 19(1): e1-47. doi: 10.1111/j.1365-2516.2012.02909.x. Epub 2012 Jul 6. PMID: 22776238.
13. World Federation of Hemophilia, 2020. Annual global survey 2019. Retrieved from https://www1.wfh.org/publications/files/pdf-1755.pdf